APPROVED: NDA Notifies COVIDEX To treat Viral Infections


Mr David Nahamya, the NDA executive director

Kampala – National Drug Authority (NDA) has approved the use of Covidex, a local herbal medicine, as a supporting treatment for viral infections, including Coronavirus.

While addressing the press at the media centre in Kampala Tuesday, Mr David Nahamya, the NDA executive director, revealed that after various assessments and inspections of the factory manufacturing the herbal medicine, they have approved its use to support the treatment of viral infections.

Doses of COVIDEX have registered good reviews after being administered to COVID-19 patients (FILE PHOTO)

“After engagements, the innovators have removed unsubstantiated claims that the product treats and prevents Covid-19 and revised it to supportive treatment in the management of viral infections. NDA has granted Covidex approval based on initial assessment, published literature and safety studies conducted by the innovator,” Mr Nahamya announced.

The product has been formulated from herbal plants that have been traditionally used to alleviate symptoms of several diseases.

However, Mr Nahamya stressed that the medicine does not cure Covid-19 but it can supplement the medicine being used by medics to treat Covid-19 patients.

The approval of COVIDEX today comes barely a fortnight since National Drug Authority (NDA) banned its use asserting that the developer, Professor Patrick Ogwang had not subjected it to the required approvals.

“For a locally manufactured drug to be approved by the National Drug Authority, it has to go through clinical trials among other requirements,” said the drug regulator officials affirmed.

Pamela Achii, the President of the Uganda Pharmaceutical Society, said on Saturday that the remedy contained the berberine plant as an active ingredient and its effectiveness has been proven in COVID-19 studies done elsewhere.

“Berberine has also been used in treatments for diabetes and liver disease. As a society, we are supporting clinical trials of the drug to quickly start,” said Achii.

Subscribe for notification